Hansoh Pharmaceutical Group Company Limited in 1 story
The narratives 3692.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
3692.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Hansoh has repeatedly monetized internally developed oncology and metabolic assets through global licensing agreements with multinational drugmakers including GSK and Regeneron.
Bear side
0 storiesNo bear-side stories for 3692.HK yet.